Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
15 July 2003Website:
http://www.adnas.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 3 min agoDividend
Analysts recommendations
Institutional Ownership
APDN Latest News
Applied DNA Sciences (APDN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
STONY BROOK, NY / ACCESSWIRE / May 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA) and the Institute of Hematology and Blood Transfusion (ÚHKT/IHBT) have announced that an abstract on the development of an enzymatic, non-viral manufacturing workflow for efficient production of clinical-grade CAR T-cell therapies has been accepted for presentation at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain from June 13 - 16, 2024. The accepted abstracts will be available on the Congress' website from May 14, 2024.
Here is how Applied DNA Sciences (APDN) and Encore Wire (WIRE) have performed compared to their sector so far this year.
Applied DNA Sciences, Inc. (APDN) Q1 2024 Earnings Call Transcript
Applied DNA Sciences (APDN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.14 per share a year ago.
STONY BROOK, NY / ACCESSWIRE / February 5, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its first quarter fiscal 2024 financial results after market close on Thursday, February 8, 2024. In conjunction with this announcement, Applied DNA management will host a conference call for analysts and members of the investment community starting at 4:30 p.m.
Applied DNA Sciences, Inc. (NASDAQ:APDN ) Q4 2023 Earnings Conference Call December 7, 2023 4:30 PM ET Company Participants Sanjay Hurry - Head of IR Beth Jantzen - CFO James Hayward - Chairman, President and CEO Clay Shorrock - Chief Legal Officer and Head of Business Development Conference Call Participants Jason McCarthy - Maxim Group Yi Chen - H.C. Wainwright Operator Good Day and welcome to the Applied DNA Sciences Fiscal Fourth Quarter 2023 Financial Results Conference Call.
Applied DNA Sciences (NASDAQ: APDN ) just reported results for the fourth quarter of 2023. Applied DNA Sciences reported earnings per share of -26 cents.
Applied DNA Sciences, Inc. (NASDAQ:APDN ) Q3 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Sanjay Hurry - Head of IR Beth Jantzen - CFO James Hayward - Chairman, President and CEO Clay Shorrock - Chief Legal Officer and Head of Business Development Conference Call Participants Jason McCarthy - Maxim Group Operator Good day, and welcome to the Applied DNA Sciences Inc. Fiscal Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded.
Investors tend to have a love-hate relationship with penny stocks. On the one hand, they offer the possibility of fascinating returns, due to the underlying stock's volatility, and the ability to purchase large shares with relatively little capital.
What type of business is Applied DNA Sciences?
Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
What sector is Applied DNA Sciences in?
Applied DNA Sciences is in the Healthcare sector
What industry is Applied DNA Sciences in?
Applied DNA Sciences is in the Diagnostics & Research industry
What country is Applied DNA Sciences from?
Applied DNA Sciences is headquartered in United States
When did Applied DNA Sciences go public?
Applied DNA Sciences initial public offering (IPO) was on 15 July 2003
What is Applied DNA Sciences website?
https://www.adnas.com
Is Applied DNA Sciences in the S&P 500?
No, Applied DNA Sciences is not included in the S&P 500 index
Is Applied DNA Sciences in the NASDAQ 100?
No, Applied DNA Sciences is not included in the NASDAQ 100 index
Is Applied DNA Sciences in the Dow Jones?
No, Applied DNA Sciences is not included in the Dow Jones index
When does Applied DNA Sciences report earnings?
The next expected earnings date for Applied DNA Sciences is 09 August 2024